FDA designates Omeros’ OMS721 for accelerated review for stem cell transplant-associated clotting disorder; shares … – Seeking Alpha
Seeking Alpha |
FDA designates Omeros' OMS721 for accelerated review for stem cell transplant-associated clotting disorder; shares …
Seeking Alpha Omeros (OMER +9.3%) is up on modestly higher volume in response to its announcement that the FDA has designated lead candidate OMS721 a Breakthrough Therapy for the treatment of patients with high-risk hematopoietic stem cell transplant-associated … FDA Grants Breakthrough Therapy Designation to Omeros' MASP-2 Inhibitor OMS721 for the Treatment of High-Risk … |
